The effect of Nigella sativa on Non-Alcoholic Fatty Liver Disease(NAFLD)

The effect of Nigella sativa consumption on lipid profile, liver enzymes, inflammatory factors and hepatic steatosis in patients with Non-Alcoholic Fatty Liver Disease(NAFLD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100524004010N25

Enrollment

Registered

2018-07-24

Start date

2017-02-28

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Other specified inflammatory liver diseases

Interventions

Intervention 1: Intervention group: 2 gr per day nigella sativa daily for 3 months. Intervention 2: Placebo group: 2 gr per day starch daily for 3 months.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 18 years old and older Evidence of nonalcoholic steatohepatitis in Fibroscan (Controlled Attenuation Parameter (CAP) score> 263) absence of pregnancy and lactation

Exclusion criteria

Exclusion criteria: Unwillingness to continue study for any reason.

Design outcomes

Primary

Measure	Time frame
HOMA. Timepoint: Begining and end of the study. Method of measurement: Calculation.;TNF-a. Timepoint: Begining and end of the study. Method of measurement: Elisa.;IL-6. Timepoint: Begining and end of the study. Method of measurement: Elisa.;Hepatic Steatosis. Timepoint: Begining and end of the study. Method of measurement: Ultrasound.;LDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;HDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;TG. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;Total Cholesterol. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;Serum Insulin. Timepoint: Begining and end of the study. Method of measurement: Radioimmunoassay.;FBS. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kits.;AST. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kits.;ALT. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;Total energy intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Carbohydrate intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Protein intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total fat intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;SFA intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;PUFA intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;MUFA intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Fiber intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.	—

Measure

Time frame

HOMA. Timepoint: Begining and end of the study. Method of measurement: Calculation.;TNF-a. Timepoint: Begining and end of the study. Method of measurement: Elisa.;IL-6. Timepoint: Begining and end of the study. Method of measurement: Elisa.;Hepatic Steatosis. Timepoint: Begining and end of the study. Method of measurement: Ultrasound.;LDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;HDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;TG. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;Total Cholesterol. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;Serum Insulin. Timepoint: Begining and end of the study. Method of measurement: Radioimmunoassay.;FBS. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kits.;AST. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kits.;ALT. Timepoint: Begining and end of the study. Method of measurement: Enzymatic methods using a kit.;Total energy intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Carbohydrate intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Protein intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total fat intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;SFA intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;PUFA intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;MUFA intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Fiber intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.

—

Secondary

Measure	Time frame
Total energy intake. Timepoint: Begining and end of the study. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hekmatdoost

Shahid Beheshti University of Medical Sciences, National Nutrition and Food Technology Research

a_HEKMAT2000@YAHOO.COM+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026